Malignant hyperthermia (MH) is a pharmacogenetic syndrome wherein exposure to halogenated volatile anesthetics or to depolarizing muscle relaxants during general anesthesia may trigger a life-threatening hypermetabolic state driven by excessive Ca 2+ release from the sarcoplasmic reticulum (SR) of skeletal muscle (1) . Over 25 y ago, the acute administration of dantrolene was shown to be highly effective at aborting an episode of MH (2) , but the mechanism and site of action have been incompletely resolved because of conflicting reports on the ability of dantrolene to inhibit the SR Ca 2+ release channel (RyR1) in different experimental preparations (3, 4) . In PNAS, Choi et al. from the Launikonis laboratory in Queensland, Australia, now provide evidence in skinned muscle fibers from rat that inhibition of SR Ca 2+ release by dantrolene is Mg 2+ -dependent, and that suppression of halothane or caffeine-induced Ca 2+ waves in human MH muscle requires an elevation of Mg 2+ above basal levels (5). These observations offer a mechanism to reconcile conflicting reports on whether dantrolene is able to inhibit RyR1 in reductionist experimental systems, and suggest that a modest degree of metabolic stress, sufficient to reduce local [ATP] and release Mg 2+ , is required for the drug to suppress an impending episode of MH.
Dantrolene Reduced the Mortality of MH More than 10-Fold
The initial description of MH was in an Australian family with 10 anesthesia-related deaths (6) , and so it is fitting that this most recent advance in understanding the basis for dantrolene's remarkable efficacy in preventing loss of life has come from a group in Queensland. MH presents with a rise of end-tidal CO 2 , sinus tachycardia, and skeletal muscle rigidity, followed by fever, hyperkalemia, and acidosis. If the signs of an MH crisis are not recognized, the mortality is 70-80% in the absence of intervention. The genetic susceptibility to MH is inherited as an autosomal dominant trait, most often arising from mutations of RYR1 encoding the Ca 2+ release channel of skeletal muscle (7, 8) . Over 30 causative mutations of RYR1 have been identified in MH families (https://emhg.org/genetics/mutations-in-ryr1/), many of which represent "private" mutations found in only one kindred. Viewed from the patient's perspective, 70% of MH-susceptible individuals, as identified by in vitro caffeine-halothane contracture testing, will have a mutation of RYR1. Mutation of a second MH gene, CANA1S, encoding for the voltage-sensing subunit of the skeletal muscle L-type Ca 2+ channel that is coupled to activation of RyR1, occurs in only about 1% of cases (9) . Dantrolene is the only available drug approved for the management of MH, and the clinical impact of dantrolene therapy has been dramatic. Discontinuation of the inciting anesthetic agent reduces mortality from >70-30%, and with administration of dantrolene mortality is <5% (2.5 mg/kg, producing a blood level of ∼5 μM) (10). Although it has been known for over 40 y that the muscle relaxant properties of dantrolene are caused by uncoupling the excitation-contraction mechanism of skeletal muscle (11) , the molecular target and the mechanism of action have remained open questions that are still under investigation. A consistent picture has emerged that dantrolene suppresses the release of Ca 2+ from the SR, without affecting neuronal excitability, neuromuscular transmission, propagation of action potentials in skeletal muscle, or the intramembranous charge displacement by the voltagesensors of the L-type Ca 2+ channel (3, 4, 12) . The controversy has been whether dantrolene acts directly on the Ca 2+ release channel RyR1 or suppresses release through indirect actions on other molecular components of the SR. Evidence in favor of a direct action includes the identification of dantrolene binding sites with nanomolar affinity mapped to RyR1 (13, 14) , dantrolene inhibition of Ca 2+ release from isolated heavy SR vesicles, and dantrolene block of [ has been observed with fatigue of mammalian skeletal muscle by repetitive stimulation ex vivo, but only after several minutes of activity when the tetanic force began to precipitously decline, most likely because of a critical reduction of ATP (18) . The metabolic stress of an MH crisis will likely also produce a decline of ATP sufficient to raise cytosolic Mg 2+ to 1.5 mM or even greater. But then, why is prophylactic dantrolene so effective in preventing halothane-induced MH for studies of porcine stress syndrome (22) or decreasing the incidence of even mild signs of impending MH in patients (elevated end-tidal CO 2 and masseter muscle rigidity)? Either a substantial reduction of ATP and increase of Mg 2+ occurs before signs of a hypermetabolic state are detectable, or the dynamics for supporting sustained waves of halothane-triggered Ca 2+ release are different for intact fibers compared with the skinned fiber preparation with its enormous reservoir of "cytoplasm."
